Quick summary
Gramicidin is a mixture of 15-amino acid antimicrobial peptides from Bacillus brevis that form ion-conducting channels in bacterial membranes. It is FDA-approved as a topical ophthalmic antibiotic (in Neosporin Ophthalmic) and serves as a canonical model in ion channel biophysics.
Overview
Gramicidin (gramicidin D) is a mixture of linear 15-amino acid antimicrobial peptides produced by Bacillus brevis, comprising gramicidin A (~80%), B (~5%), and C (~15%). It is used topically as an antibiotic and is a component of Neosporin Ophthalmic Solution. Gramicidin acts by forming ion-conducting channels in bacterial cell membranes. Gramicidin S is a structurally distinct cyclic variant.
Mechanism of action
Gramicidin A, B, and C form head-to-head dimers that insert into lipid bilayers as single-stranded beta-helices, creating cation-selective transmembrane pores approximately 4 Å in diameter. These channels allow free diffusion of monovalent cations (Na+, K+, H+) but exclude divalent cations and anions. Disruption of the bacterial membrane ion gradient collapses the electrochemical potential, inhibiting ATP synthesis and nutrient transport, ultimately causing cell death. Channel formation is particularly effective in gram-positive bacterial membranes. Gramicidin is too cytotoxic for systemic use due to erythrocyte lysis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| ophthalmic bacterial infection | topical | 1–2 drops | every 4–6 hours | Neosporin Ophthalmic: gramicidin 0.025 mg/mL; instill 1–2 drops every 4 hours for up to 7–10 days |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Gramicidin has been used topically since the 1940s and remains in Neosporin Ophthalmic (gramicidin 0.025 mg/mL + neomycin + polymyxin B). It is among the first antibiotics to have its ion channel mechanism elucidated and serves as a canonical model system in biophysics research. Gramicidin's channel properties are studied with single-channel electrophysiology and have informed the design of synthetic ion channel-forming peptides. Gramicidin S (cyclic) is studied for broader antibacterial applications including MRSA, with ongoing analog development.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Gramicidin for synergistic effects.
Legal status
Gramicidin is FDA-approved as a topical ophthalmic antibiotic component. Available in combination products (e.g., Neosporin Ophthalmic Solution). Prescription required for ophthalmic formulations; combination OTC products may be available.
Sourcing & access
Prescription required
Gramicidin is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Gramicidin (gramicidin D) is a mixture of linear antimicrobial peptides produced by Bacillus brevis, comprising gramicidin A (~80%), B (~5%), and C (~15%). It is FDA-approved as a topical ophthalmic antibiotic component in Neosporin Ophthalmic Solution.
Gramicidin forms head-to-head dimers that insert into lipid bilayers as single-stranded beta-helices, creating 4-angstrom cation-selective transmembrane pores. These channels allow free diffusion of sodium, potassium, and hydrogen ions, collapsing the bacterial membrane electrochemical potential and causing cell death.
Gramicidin is safe for topical and ophthalmic use. Side effects include local eye irritation and allergic contact dermatitis. It is too cytotoxic for systemic use due to erythrocyte lysis, which is why it is restricted to topical formulations.
Gramicidin's ion channel mechanism is not selective enough to spare mammalian red blood cells, causing hemolysis at systemic concentrations. This limits it to topical and ophthalmic applications where systemic absorption is minimal.
Research references
- Gramicidin channel structure and ion transport mechanismsPubMed
- Gramicidin D topical antibiotic: clinical applications in eye and ear infectionsPubMed
- Ion channel-forming antibiotics: gramicidin and bacterial membrane disruptionPubMed
- Gramicidin antimicrobial peptides and their mechanisms of resistancePubMed